Research programme: neurological disorder therapeutics - Nido Biosciences
Latest Information Update: 18 Jul 2023
At a glance
- Originator Nido Biosciences
- Class Anti-inflammatories; Antidementias; Small molecules
- Mechanism of Action Cell death inhibitors; Protein aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Neurological disorders; Tauopathies
- Research Frontotemporal dementia
Most Recent Events
- 12 Jul 2023 Research programme: Neurological disorder therapeutics - Nido Biosciences is available for licensing as of 12 Jul 2023. https://nidobio.com/ (Nido Biosciences website, July 2023)
- 12 Jul 2023 Early research in Amyotrophic lateral sclerosis in USA (unspecified route) (Nido Biosciences pipeline, July 2023)
- 12 Jul 2023 Early research in Frontotemporal dementia in USA (unspecified route) (Nido Biosciences pipeline, July 2023)